FDA approved the oral antiviral Paxlovid for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death. Paxlovid is the fourth drug — and first oral antiviral pill — approved by the FDA to treat COVID-19 in adults. (You can also read about it on NCPA’s COVID-19 therapeutics page.) Upon the New Drug Application for Paxlovid, pharmacists may continue to prescribe Paxlovid nationwide, consistent with the terms of the FDA-approved USPI, the FDA emergency use authorization as specified in the EUA Fact Sheets, and the conditions of eleventh amendment of the PREP Act declaration while distribution of federally purchased product continues.
NCPA
